RSM logo
JRSM

Home Current issue Browse archive Alerts About the journal Feedback
 
J R Soc Med 1986;79:210-211
© 1986 Royal Society of Medicine

This Article
Right arrow Send a Quick Comment
Right arrow Alert me when this article is cited
Right arrow Alert me when Quick Comments are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Paisey, R. B.
Right arrow Articles by Gingell, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Journal of the Royal Society of Medicine, Vol 79, Issue 4 210-211, Copyright © 1986 by Royal Society of Medicine

ORIGINAL ARTICLES

Effects of cyproterone acetate and a long-acting LHRH analogue on serum lipoproteins in patients with carcinoma of the prostate

RB Paisey, C Kadow, C Bolton, M Hartog and JC Gingell

Fasting serum lipoproteins were measured in 10 untreated patients with carcinoma of the prostate (Group I), 17 patients with non-malignant urological disorders (Group II), and 12 patients on cyproterone acetate (Group III) and 5 on a long-acting luteinizing hormone-releasing hormone (LHRH) analogue (Group IV) for at least 2 months for carcinoma of the prostate. Total high-density lipoprotein (HDL) cholesterol levels were significantly lower in patients in Group III than all the other groups. Very low-density lipoprotein (VLDL) triglyceride levels were significantly higher in patients in Group III than those in Groups II and IV. These results suggest a potentially adverse effect of cyproterone acetate, but not of the long-acting LHRH analogue, on serum lipids, which is likely to be of relevance only in younger patients.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 The OncologistHome page
D. G. McLeod
Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer
Oncologist, February 1, 1997; 2(1): 18 - 27.
[Abstract] [Full Text] [PDF]


How Not to be a Doctor

 Developing the Wise Doctor George Guthrie